The impact of neoadjuvant chemotherapy on patients with T1N0M0 triple-negative and HER-2 positive breast cancer:a retrospective analysis based on the SEER database

The utilization of neoadjuvant chemotherapy (NAC) originated in the treatment of locally advanced breast cancer (BC). Our study is designed to elucidate the effects of NAC on patients with T1N0M0 triple-negative and HER-2 positive BC.